ArticleAging2014
Rapamycin in preventive (very low) doses.
Article in Aging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The autophagy-activating kinase ULK1 mediates clearance of free α-globin in β-thalassemia.Science translational medicine · 2019Article
- The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis.International journal of molecular sciences · 2018Review
- Calorie restriction effects on circadian rhythms in gene expression are sex dependent.Scientific reports · 2017Article
- From rapalogs to anti-aging formula.Oncotarget · 2017Review
- Identification ofAging · 2016Article
- Mammalian Target of Rapamycin Inhibition With Rapamycin Mitigates Radiation-Induced Pulmonary Fibrosis in a Murine Model.International journal of radiation oncology, biology, physics · 2016Article
- Article
- Inhibitors of mTOR in aging and cancer.Oncotarget · 2015Article
- TOR-inhibitors as gero-suppressors.Aging · 2015Article
- Rejuvenating immunity: "anti-aging drug today" eight years later.Oncotarget · 2015Article
- iPSC-MSCs and islet allograft tolerance.Oncotarget · 2015Article
- Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.Oncotarget · 2015Article
- Koschei the immortal and anti-aging drugs.Cell death & disease · 2014Review
- Gerosuppression in confluent cells.Aging · 2014Article
- Comparison of rapamycin schedules in mice on high-fat diet.Cell cycle (Georgetown, Tex.) · 2014Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.